According to a recent LinkedIn post from Touchlight, the company is highlighting new application data comparing its proprietary doggybone DNA (dbDNA) format with conventional plasmid DNA for in vivo protein expression. The post indicates that the study used Sartorius Polyplus non‑viral delivery reagents, including in vivo‑jetPEI and in vivo‑jetRNA+.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn content suggests that dbDNA enabled smaller delivery complexes and higher, more sustained protein expression in multiple tissues such as lung, spleen, and muscle. It also notes improved durability following both intravenous and intramuscular administration, implying potential performance advantages in non‑viral delivery applications.
For investors, this type of data may signal continued technical progress in Touchlight’s DNA platform, which could strengthen its positioning in gene therapy, vaccines, and other in vivo modalities. If comparable performance advantages are validated by partners or customers, the technology could enhance the company’s licensing appeal and support future revenue opportunities in the nucleic acid therapeutics ecosystem.